long-acting injectables

Actionable Insights Powered by AI

Battle for HIV PrEP Market: Gilead’s Twice-Yearly Injection Challenges GSK’s Apretude

HIV prevention, PrEP, lenacapavir, Apretude, long-acting injectables, Gilead Sciences, GSK, ViiV Healthcare